Navigation Links
Brachytherapy For Breast Cancer Can Be Risky

A new study published in the June 2006 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of ASTRO, the American Society //for Therapeutic Radiology and Oncology, says that doctors in New England have found that patients receiving partial radiation for the breast in order to combat breast cancer have the risk of developing a seroma.

A seroma is retention of fluid in the breast, which can complicate matters since it requires aspiration. The study followed 38 women who had the procedure after undergoing lumpectomy surgery to remove the cancer. After the surgery, a balloon brachytherapy method is used to place a balloon in the space occupied by the tumor.

Radiation Oncologists then deliver high doses of radiation locally in order to kill off any remaining cancer cells. In the current study 76.3 percent of them developed seroma in their breast and 68.4 percent of the patients had it for over 6 months.

'Seroma is not infrequent after surgery, but it typically resolves itself within a few weeks. However, with these patients, the seroma didn’t resolve,' said Suzanne B. Evans, M.D., M.P.H., lead author of the study and a radiation oncology resident at Tufts-New England Medical Center. 'We look forward to other studies in which the device is placed post-operatively to determine whether this lowers the rate of seroma formation.'


'"/>




Page: 1

Related medicine news :

1. Brachytherapy for breast cancer
2. Brachytherapy Shows Promise for Cancer Treatment
3. Prostate Brachytherapy Causes Fewer Side Effects Than Surgery
4. Consensus on "Combination Therapy" for Breast Cancer
5. Breast cancer treatment to be determined by gene test
6. Breast Feeding prevents obesity later on in life
7. Breast milk is essential
8. Breast Cancer Surgery Causes Psychological problems
9. Breast cancer evidence
10. Letrozole Beats Tamoxifen in Breast Cancer Therapy
11. Breast screening among diabetic women
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/29/2016)... ... ... On Tuesday, April 26, 2016 members of the HomeTown Health network, a ... Deal on SB 258, the “Rural Health Care Relief” Bill. , The bill, which ... to individuals and corporations which donate directly to a “rural hospital” in Georgia, and ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White House ... their loans, more information about their loan terms and accounts, and more protections ... debt, including federal and private loans, has reached $1.3 trillion, with 43 million ...
(Date:4/29/2016)... ... April 29, 2016 , ... A ... born with severe congenital diaphragmatic hernia have better survival rates if surgery is ... hernia (CDH)—a condition where the diaphragm fails to form completely, letting abdominal organs ...
(Date:4/29/2016)... ... 2016 , ... Mobility Designed is redefining mobility with their patent pending ... Crutch evenly distributes body weight from the elbow to the forearm. In consumer ... than with other crutches. , Co-founders Max and Liliana Younger were inspired to design ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type of skin ... blame for the majority of skin cancer deaths. More than 10,000 people are expected to ... at diagnosis is 62, it is the one of the most commonly diagnosed cancers in ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of oral drug ... the upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... in New York . Nadav Kidron ... the conference. Presentation Details:   ...
(Date:4/28/2016)... New market research titled ... report that provides an overview of the Osteoarthritis,s ... identifying new targets and MOAs to produce first-in-class ... in this H1 2016 Osteoarthritis Pipeline report include ... Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, Inc., ...
(Date:4/27/2016)... , April 27, 2016   ... 42% Growth in Recurring Consumable Sales  Clinical ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of ... its sales for the first quarter ended March 31, ... the execution of its commercial strategy. First ...
Breaking Medicine Technology: